I. Romon, G. Rey, L. Mandereau-Bruno, A. Weill, E. Jougla, E. Eschwege, D. Simon, C. Druet and A. Fagot-Campagna
Diabetic Medicine, 2014, 31(8), 946-953. DOI: 10.1111/dme.12435
To compare the 5-year mortality (overall and cause-specific) of a cohort of adults pharmacologically treated for diabetes with that of the rest of the French adult population.
In 2001, 10 000 adults treated for diabetes were randomly selected from the major French National Health Insurance System database. Vital status and causes of death were successfully extracted from the national registry for 9101 persons. We computed standardized mortality ratios.
Over 5 years, 1388 adults pharmacologically treated for diabetes died (15% of the cohort, 32.4/1000 person-years). An excess mortality, which decreased with age, was found for both genders [standardized mortality ratio 1.45 (1.37-1.52)]. Excess mortality was related to: hypertensive disease [2.90 (2.50-3.33)], ischaemic heart disease [2.19 (1.93-2.48)], cerebrovascular disease [1.76 (1.52-2.03)], renal failure [2.14 (1.77-2.56)], hepatic failure [2.17 (1.52-3.00)] in both genders and septicaemia among men [1.56 (1.15-2.09)]. An association was also found with cancer-related mortality: liver cancer in men [3.00 (2.10-4.15)]; pancreatic cancer in women [3.22 (1.94-5.03)]; colon/rectum cancer in both genders [1.66 (1.28-2.12)]. Excess mortality was not observed for breast, lung or stomach cancers.
Adults pharmacologically treated for diabetes had a 45% increased risk of mortality at 5 years, mostly related to cardiovascular complications, emphasizing the need for further prevention. The increased risk of mortality from cancer raises questions about the relationship between cancer and diabetes and prompts the need for improved cancer screening in people with diabetes.
Diabetic Medicine, 2008, 25(11), 1295-1301. DOI: 10.1111/j.1464-5491.2008.02581.xHow much might cardiovascular disease risk be reduced by intensive therapy in people with screen-detected diabetes?
Diabetic Medicine, 2008, 25(12), 1433-1439. DOI: 10.1111/j.1464-5491.2008.02600.xAre there differences in cardiovascular and metabolic risk profiles among men and women with Type 2 diabetes? A cross-sectional analysis
Diabetic Medicine, 2010, 27(10), 1212-1214. DOI: 10.1111/j.1464-5491.2010.03077.xAssociations between surrogate measures of insulin resistance and waist circumference, cardiovascular risk and the metabolic syndrome across Hispanic and non-Hispanic white populations
Diabetic Medicine, 2012, 29(11), 1390-1394. DOI: 10.1111/j.1464-5491.2012.03723.xAdverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population
Diabetic Medicine, 2012, 29(12), 1524-1528. DOI: 10.1111/j.1464-5491.2012.03772.xLong-term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study
Diabetic Medicine, 2013, 30(1), 46-55. DOI: 10.1111/j.1464-5491.2012.03750.xChanges in physical activity and modelled cardiovascular risk following diagnosis of diabetes: 1-year results from the ADDITION-Cambridge trial cohort
Diabetic Medicine, 2013, 30(2), 233-238. DOI: 10.1111/j.1464-5491.2012.03765.xCardiovascular effects of GLP-1 and GLP-1-based therapies: implications for the cardiovascular continuum in diabetes?
Diabetic Medicine, 2013, 30(3), 289-299. DOI: 10.1111/j.1464-5491.2012.03746.xRetracted: Effects of fasting blood glucose, diabetes treatment, blood pressure and anti-hypertension treatment on cardiovascular disease incidence: a 30-year follow-up study of 740 incident patients with Type 2 diabetes
Diabetic Medicine, 2013, 30(3), 349-357. DOI: 10.1111/dme.12106Sulphonylureas and risk of cardiovascular disease: systematic review and meta-analysis
Diabetic Medicine, 2013, 30(10), 1160-1171. DOI: 10.1111/dme.12232Biological variation of cardiovascular risk factors in patients with diabetes
Diabetic Medicine, 2013, 30(10), 1172-1180. DOI: 10.1111/dme.12160Changes in diet, cardiovascular risk factors and modelled cardiovascular risk following diagnosis of diabetes: 1-year results from the ADDITION-Cambridge trial cohort
Diabetic Medicine, 2014, 31(2), 148-155. DOI: 10.1111/dme.12316Physiological serum bilirubin concentrations are inversely associated with the prevalence of cardiovascular autonomic neuropathy in patients with Type 2 diabetes
Diabetic Medicine, 2014, 31(2), 185-191. DOI: 10.1111/dme.12338Cardiovascular disease risk factors in the South Asian population living in Kuwait: a cross-sectional study
Diabetic Medicine, 2014, 31(5), 531-539. DOI: 10.1111/dme.12386Factors associated with statin treatment for the primary prevention of cardiovascular disease in people within 2 years following diagnosis of diabetes in Scotland, 2006-2008
Diabetic Medicine, 2014, 31(6), 640-646. DOI: 10.1111/dme.12409Does early intensive multifactorial therapy reduce modelled cardiovascular risk in individuals with screen-detected diabetes? Results from the ADDITION-Europe cluster randomized trial
Diabetic Medicine, 2014, 31(6), 647-656. DOI: 10.1111/dme.12410Type 2 diabetes mellitus and obesity in young adults: the extreme phenotype with early cardiovascular dysfunction
Diabetic Medicine, 2014, 31(7), 794-798. DOI: 10.1111/dme.12431Association of physical activity with glycaemic control and cardiovascular risk profile in 65 666 people with Type 2 diabetes from Germany and Austria
Diabetic Medicine, 2014, 31(8), 905-912. DOI: 10.1111/dme.12438Cardiovascular risk profiles in relation to newly diagnosed Type 2 diabetes diagnosed by either glucose or HbA1c criteria in Chinese adults in Qingdao, China
Diabetic Medicine, 2014, 31(8), 920-926. DOI: 10.1111/dme.12498